Palliative care and end-of-life issues in patients treated with left ventricular assist devices as destination therapy

被引：39
作者：
Swetz K.M. [1 ]
Ottenberg A.L. [1 ]
Freeman M.R. [1 ]
Mueller P.S. [1 ]
机构：
[1] Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905
来源：
Current Heart Failure Reports | 2011年 / 8卷 / 3期
关键词：
Advance care planning; Destination therapy; DT; End of life; End-stage heart failure; ESHF; Heart failure; LVAD; Medical ethics; Palliative care; Patient-caregiver communication; Preparedness planning; Psychosocial issues; Quality of care; Quality of life; Ventricular assist device;
D O I：
10.1007/s11897-011-0060-x
中图分类号：
学科分类号：
摘要：
Left ventricular assist devices as destination therapy (DT) improve quality of life for many patients with advanced heart failure. However, DT can be associated with risks such as infection, bleeding, and stroke, and may impose psychosocial strain on patients and caregivers. Furthermore, patients treated with DT eventually will die with their device in place whether death is related to the device or not. In response to these concerns, palliative medicine consultation has been suggested with standard DT care to improve focus on quality of life, symptom management, and end-of-life planning. This article reviews key issues associated with caring for patients with DT, including psychosocial, quality-of-life, caregiving, and ethical issues, and discusses end-of-life management of patients with DT, including practical considerations, but moreover, review topics regarding communication, symptom management, and provision of appropriate comfort care. © Springer Science+Business Media, LLC 2011.
引用
收藏
页码：212 / 218
页数：6
相关论文
共 50 条
[1]  
Lietz K., Long J.W., Kfoury A.G., Slaughter M.S., Silver M.A., Milano C.A., Rogers J.G., Naka Y., Mancini D., Miller L.W., Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: Implications for patient selection, Circulation, 116, 5, pp. 497-505, (2007)
[2]  
Rose E.A., Gelijns A.C., Moskowitz A.J., Et al., Long-term use of a left ventricular assist device for end-stage heart failure, N Engl J Med., 345, pp. 1435-1443, (2001)
[3]  
Long J.W., Healy A.H., Rasmusson B.Y., Et al., Improving outcomes with long-term "destination" therapy using left ventricular assist devices, J Thorac Cardiovasc Surg., 135, pp. 1353-1360, (2008)
[4]  
Park S.J., Tector A., Piccioni W., Raines E., Gelijns A., Moskowitz A., Rose E., Holman W., Furukawa S., Frazier O.H., Dembitsky W., Left ventricular assist devices as destination therapy: A new look at survival, Journal of Thoracic and Cardiovascular Surgery, 129, 1, pp. 9-17, (2005)
[5]  
Slaughter M.S., Rogers J.G., Milano C.A., Et al., Advanced heart failure treated with continuous-flow left ventricular assist device, N Engl J Med, 361, pp. 2241-2251, (2009)
[6]  
Boilson B., Schirger J., Durham III J., Et al., Transformation of LVAD destination therapy "good to great": Ever increasing survival benefit, Circulation, 120, (2009)
[7]  
Rogers J.G., Aaronson K.D., Boyle A.J., Et al., Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients, J Am Coll Cardiol, 55, pp. 1826-1834, (2010)
[8]  
Kirklin J.K., Naftel D.C., Kormos R.L., Et al., Third INTERMACS Annual report: The evolution of destination therapy in the United States, J Heart Lung Transplant, 30, pp. 115-123, (2011)
[9]  
Stevenson L.W., Pagani F.D., Young J.B., Et al., INTERMACS profiles of advanced heart failure: The current picture, J Heart Lung Transplant, 28, pp. 535-541, (2009)
[10]  
Krumholz H.M., Phillips R.S., Hamel M.B., Teno J.M., Bellamy P., Broste S.K., Califf R.M., Vidaillet H., Davis R.B., Muhlbaier L.H., Connors Jr. A.F., Lynn J., Goldman L., Resuscitation preferences among patients with severe congestive heart failure: Results from the SUPPORT project, Circulation, 98, 7, pp. 648-655, (1998)
12345